CYTK Relative Valuation
CYTK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CYTK is overvalued; if below, it's undervalued.
Historical Valuation
Cytokinetics Inc (CYTK) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -9.69. The fair price of Cytokinetics Inc (CYTK) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：66.54
Fair
-11.16
PE
1Y
3Y
5Y
Trailing
Forward
-15.47
EV/EBITDA
Cytokinetics Inc. (CYTK) has a current EV/EBITDA of -15.47. The 5-year average EV/EBITDA is -9.72. The thresholds are as follows: Strongly Undervalued below -15.17, Undervalued between -15.17 and -12.45, Fairly Valued between -7.00 and -12.45, Overvalued between -7.00 and -4.27, and Strongly Overvalued above -4.27. The current Forward EV/EBITDA of -15.47 falls within the Strongly Undervalued range.
-12.12
EV/EBIT
Cytokinetics Inc. (CYTK) has a current EV/EBIT of -12.12. The 5-year average EV/EBIT is -9.79. The thresholds are as follows: Strongly Undervalued below -14.93, Undervalued between -14.93 and -12.36, Fairly Valued between -7.21 and -12.36, Overvalued between -7.21 and -4.64, and Strongly Overvalued above -4.64. The current Forward EV/EBIT of -12.12 falls within the Historic Trend Line -Fairly Valued range.
85.04
PS
Cytokinetics Inc. (CYTK) has a current PS of 85.04. The 5-year average PS is 182.18. The thresholds are as follows: Strongly Undervalued below -211.96, Undervalued between -211.96 and -14.89, Fairly Valued between 379.25 and -14.89, Overvalued between 379.25 and 576.32, and Strongly Overvalued above 576.32. The current Forward PS of 85.04 falls within the Historic Trend Line -Fairly Valued range.
-13.39
P/OCF
Cytokinetics Inc. (CYTK) has a current P/OCF of -13.39. The 5-year average P/OCF is -10.79. The thresholds are as follows: Strongly Undervalued below -18.66, Undervalued between -18.66 and -14.72, Fairly Valued between -6.85 and -14.72, Overvalued between -6.85 and -2.91, and Strongly Overvalued above -2.91. The current Forward P/OCF of -13.39 falls within the Historic Trend Line -Fairly Valued range.
-11.07
P/FCF
Cytokinetics Inc. (CYTK) has a current P/FCF of -11.07. The 5-year average P/FCF is -11.10. The thresholds are as follows: Strongly Undervalued below -20.07, Undervalued between -20.07 and -15.59, Fairly Valued between -6.61 and -15.59, Overvalued between -6.61 and -2.12, and Strongly Overvalued above -2.12. The current Forward P/FCF of -11.07 falls within the Historic Trend Line -Fairly Valued range.
Cytokinetics Inc (CYTK) has a current Price-to-Book (P/B) ratio of -15.61. Compared to its 3-year average P/B ratio of -54.74 , the current P/B ratio is approximately -71.48% higher. Relative to its 5-year average P/B ratio of -28.93, the current P/B ratio is about -46.03% higher. Cytokinetics Inc (CYTK) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -8.65%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -6.54% , the current FCF yield is about -100.00% lower.
-15.61
P/B
Median3y
-54.74
Median5y
-28.93
-5.73
FCF Yield
Median3y
-8.65
Median5y
-6.54
Competitors Valuation Multiple
The average P/S ratio for CYTK's competitors is , providing a benchmark for relative valuation. Cytokinetics Inc Corp (CYTK) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 318.14%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CYTK increased by 41.45% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 463.00K to 1.94M.
The secondary factor is the Margin Expansion, contributed -54.39%to the performance.
Overall, the performance of CYTK in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Cytokinetics Inc (CYTK) currently overvalued or undervalued?
What is Cytokinetics Inc (CYTK) fair value?
How does CYTK's valuation metrics compare to the industry average?
What is the current P/B ratio for Cytokinetics Inc (CYTK) as of Dec 05 2025?
What is the current FCF Yield for Cytokinetics Inc (CYTK) as of Dec 05 2025?
What is the current Forward P/E ratio for Cytokinetics Inc (CYTK) as of Dec 05 2025?